Appendix 4C - Quarterly Cashflow Report
Starpharma today released its Appendix 4C - Quarterly Cashflow Report for the period ended 30 June 2013.
Eureka Report: Five bargains for under a buck
Eureka Report small caps reporter Brendon Lau interviewed Jackie Fairley citing Starpharma as a high-value biotech stock.
“I can’t remember a time when Starpharma had this many potential milestones over a relatively short period and even its chief executive, Jackie Fairley, describes the next six-months as the “most exciting” window in Starpharma’s history.”
Starpharma appoints Business Development executive
Starpharma today announced a new senior appointment to its experienced and successful business development team. Dr Tony Eglezos has been appointed to the position of VP of Business Development.
Tony has worked for more than 20 years in the pharmaceutical industry in Australia, the US and Europe for companies including CSL, Amgen, Abbott Labs and Abbott Australia.
ARC grant for Starpharma's targeted drug delivery
Starpharma today announced it had been successful in securing a $548,000 ARC Linkage grant in partnership with Monash University, to further advance the Company’s dendrimer technology in targeted drug delivery including antibody-drug conjugates (ADCs).